Fetal Therapy: Where Do We Stand by Sebastian Illanes & Javier Caradeux
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Fetal Therapy: Where Do We Stand 
Sebastian Illanes and Javier Caradeux 
Fetal Medicine Unit, Department of Obstetrics & Gynaecology and  
Laboratory of Reproductive Biology, Universidad de los Andes 
Chile 
1. Introduction 
The last three decades have seen enormous scientific and technological advances, which 
have allowed the emergence of fetal medicine as a discipline and the possibility of fetal 
therapy. The development of different tools such as ultrasound, allows inspection and 
examination of the fetus, and a wide range of invasive procedures can be used for diagnostic 
and therapeutic purposes. 
The value of a fetal therapy relates to the balance between benefits and risks of the in-uterus 
intervention, contrasted with the natural history and prognosis of each pathological 
condition. Several studies have shown that any problem diagnosed prenatally, usually has a 
worse prognosis than when the diagnosis is made postnatally. This improvement of 
prognosis with time relates to the gestational age at diagnosis, because of early detection of 
the most severe cases. It also relates to complications occurring during the pregnancy such 
as the emergence of associated genetic syndromes resulting in the worst prognosis cases 
being excluded by for example miscarriage. Therefore we should be very cautious about 
counselling a pregnant woman based on neonatal data and we need to adjust the prognosis 
given depending on the gestational age of the pregnancy. 
We have classified the possible antenatal therapeutic interventions as transplacental 
treatment, invasive procedures, including transfusion and fetal surgery and future 
perspectives which we consider in an experimental stage but with clear possibilities of 
success. 
2. Transplacental therapy: Fetal pharmacotherapy 
Pharmacological therapy can be used to treat fetal disorders or improve the ability of the 
fetus to adapt to extra-uterine life. The transplacental route is the most commonly used 
way to administer drugs. However, transfer can be poor either because of the nature of 
the drug itself (e.g. digoxin) or if the condition requiring treatment reduces placental 
function (e.g. a hydropic placenta). Other approaches to drug therapy include direct fetal 
administration by the intra-amniotic route but these have a very limited role at present 
because of the invasive nature of the procedures and because very little is known 
regarding the effects of fetal physiology on fetal drug distribution and effects (Koren G. 
2002 - Thein AT. 1998). 
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2.1 Therapies to improve the ability of the fetus to adapt to extra-uterine life  
Several methods have been used to accelerate fetal maturation in fetuses at risk of preterm 
delivery, and the example most extensively studied and used is corticosteroids for lung 
maturity. Liggins was the first to describe this effect in 1969 (Liggins GC. 1969), and 40 years 
later the administration of these drugs remain the most important step to prevent 
respiratory distress syndrome and intraventricular haemorrhage in preterm infants (Crowley 
P. 2004 – Onland W 2011). The effect of treatment is optimal if the baby is delivered more 
than 24 hours and less than seven days after the start of treatment (Crowley. 2004 – 
Bronwnfoot FC. 2008). Use of repeat corticosteroid courses is at the moment under review. 
Some studies have shown a potential benefit of weekly repeat courses of antenatal 
corticosteroids in the occurrence and severity of neonatal respiratory disease but the short-
term benefits are associated with a reduction in weight and head circumference, by the 
moment weekly repeated courses of steroids are not recommended (Bevilacqua E. 2010 - 
ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7). More studies are needed to 
assess the long term effect of repeated steroid exposure on the developing human brain 
(Bevilacqua E. 2010 - ACOG Committee Opinion. No. 402 – RCOG Guideline No. 7 – Lamer P. 
2002 – Crowther CA. 2004). Some authors have suggested a role for corticosteroids in elective 
term cesarean in order to reduce the higher incidence of respiratory distress presented by 
this group compared with vaginal term deliveries; however more studies are needed to 
recommend this approach (Sotiriadis A. 2009). 
2.2 Preventative therapies 
A number of modalities have been studied over the years to try to prevent fetal serious 
disease that can lead to fetal death or serious long-term sequel in the child. An example of 
this strategy is the prevention of neural tube defects (NTDs). These conditions include open 
spina bifida, anencephaly and encephalocele, and complicate 1 or 2 every 1000 pregnancies 
in the UK (Abramsky L. 1999), and can be prevented by the administration of folic acid 
during pregnancy (MRC. 1991 - Czeizel AE. 1992). This is the first congenital malformation to 
be primarily prevented by pharmacological fetal therapy (RCOG 2003). In 1996, the US Food 
and Drug Administration, initiated folic acid fortification of flour and mean folate levels in 
the population improved with substantial decrease in the risk of NTDs (Koren G. 2002), this 
policy have been implemented in many countries (RCOG 2003). Recent studies demonstrate 
this protective role of folate for NTDs, showing a protective effect of daily folic acid 
supplementation in preventing the disease (RR 0.28, 95% CI 0.15 to 0.52), with a significant 
protective effect for recurrence (RR 0.32, 95% CI 0.17 to 0.60) (De-Regil LM. 2010). 
Another successful strategy is the maternal administration of IVIg and/or corticosteroids to 
the mother to prevent severe fetomaternal alloimmune thrombocytopenia (FMAIT). This 
pathology occurs when a woman becomes alloimmunised against fetal platelet antigens 
inherited from the father of the baby which are absent from the maternal platelets. The most 
common of them is anti-HPA-1 (Kaplan C. 2002). This condition is more frequent than is 
often realised since it occurs in about 1 in 1200 births (Mueller EC. 1985 - Blanchette VS 1990 – 
Kaplan C. 1994). The main complication of this disease is bleeding which may have severe 
consequences such as fetal intracranial haemorrhage (ICH) resulting in death or long-term 
disability (Montemagno R. 1994). Unlike red cell alloimmunisation, this disease often affects 
the first pregnancy, possibly due to the presence of the antigens in the trophoblast. The risk 
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of recurrence in subsequent pregnancies with increasing severity is very high being 50-100% 
depending on the zygocity of the father for the relevant antigen (Murphy MF. 2000). Bussel 
(Bussel JB. 1996) demonstrated that treatment with IVIg produced an increase in the platelet 
count of fetuses with alloimmune thrombocytopenia and observational studies have 
suggested an improvement in clinical outcome and reduction in the risk for intracranial 
haemorrhage when IVIg is administered to the mother throughout pregnancy (Rayment R. 
2005). Maternal therapy with IVIg may result in a fetal platelet count exceeding 50 x 109/l in 
67% of pregnancies with a history of sibling affected by FMAIT (Birchall JE. 2003), reducing 
the need of FBS and transfusions avoiding the complications of this technique. Although, 
the optimal management of FMAIT remains unclear and further trials would be required to 
determine optimal treatment for this condition. (Rayment R.2011) 
In recent years, observational studies have indicated a relationship between antenatal 
treatment with magnesium sulfate in preeclampsia and preterm deliveries, and a 
consequent decrease in cerebral palsy in preterm infants with low birth weight (Nelson KB. 
1995 – Hirtz DG. 1998). Many randomized controlled trials have been conducted to examine 
this association. Recent meta-analysis conclude that the use of magnesium sulfate 
administered to patients at risk of preterm delivery before 34 weeks reduces the risk of 
cerebral palsy and gross motor dysfunction, without increase in pediatric mortality 
(Costantine M. 2009 - Conde-Agudelo A. 2009 - Doyle LW. 2009). 
2.3 Therapy for fetal disease 
Fetal arrhythmias are good examples of pathologies which can be treated by therapeutic 
fetal drug administration. Although tachycardia (fetal ventricular heart rate faster than 180 
bpm.) is sometimes intermittent, the chance of hemodynamic complications and 
development of fetal hydrops remains high (Yasuki M. 2009). The indications for therapy 
may depend on its etiology, fetal age and disease severity (McElhinney DB. 2010 - Strasburger 
JF 2010). For intermittent tachycardia, treatment is generally unnecessary, unless hydrops or 
cardiac dysfunction is evident. In preterm fetuses, sustained tachycardia should probably be 
treated regardless of cardiac dysfunction or hydrops, because these sequelae can develop 
rapidly (McElhinney DB. 2010). When the patient presents with hydrops most arrhythmias 
can often be controlled with transplacental treatment, but the mortality in this group 
remains quite high (Conde-Agudelo A. 2009).  
Over the years, most antiarrhythmic agents have been used to treat fetal supraventricular 
tachycardia (McElhinney DB. 2010) and most fetuses are successfully treated in utero by 
transplacental administration of antiarrhythmic drugs (Yasuki M. 2009). Digoxin is widely 
accepted as a first-line antiarrhythmic drug. Sotalol, flecainide and amiodarone are used as 
second-line drugs when digoxin fails to achieve conversion to sinus rhythm (Yasuki M. 2009 
- McElhinney DB. 2010). For fetuses with hydrops, digoxin is rarely effective (Yasuki M. 2009 
- McElhinney DB. 2010 - Strasburger JF 2010) because the placental transfer of the digoxin is 
limited. Hence, sotalol or flecainide, which have good placental transfer ability, should be 
used from the beginning of fetal treatment for hydrops. (Yasuki M. 2009 - McElhinney DB. 
2010 - Strasburger JF 2010) 
The safety of the mother is of great concern when managing fetal tachycardia, even after 
some studies did´nt find any serious effects in the mother (Simpson JM. 1998). 
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Administration of antiarrhythmic drugs for intrauterine treatment may cause pro-
arrhythmia and threaten the mother. So ECG monitoring is recommended during dosage 
increase (Yasuki M. 2009). However, these complications are generally tolerable and 
reversible (Strasburger JF 2010). 
Although intrauterine treatment is very effective in fetuses with tachycardia, treatment after 
delivery is also very effective. Hence, decisions for which cases are treated in utero or 
postnatally is often difficult. So, it is important not to select postnatal treatment too quickly 
in premature gestation, even when the fetus has already developed hydrops (Yasuki M. 
2009). Once the tachycardia is converted to sinus rhythm, the hydrops will recover and the 
fetus can be delivered at term by vaginal birth. However, when the hydrops continues for 
more than 2 weeks without conversion of tachycardia, postnatal treatment is recommended 
(Yasuki M. 2009). 
The efficacy of prenatal treatment for fetal bradicardia (fetal ventricular heart rate is less 
than 100 bpm) is limited compared with treatment for fetal tachycardia. Approximately half 
of all cases are caused by associated congenital heart disease, and the remaining cases that 
have normal cardiac structure are often caused by maternal SS-A antibody (Yasuki M. 2009). 
Beta stimulants and steroids have been reported as effective transplacental treatments for 
fetal AV block (Yasuki M. 2009). But the utility of these drugs still controversial (McElhinney 
DB. 2010 - Strasburger JF 2010). Work is being done to develop leads and devices to improve 
fetal pacing (Strasburger JF 2010). 
3. Invasive procedure  
3.1 Transfusion therapy 
3.1.1 Red cell isoimmunisation 
Haemolytic disease of the fetus and newborn (HDFN) is due to maternal alloantibodies 
directed against paternally inherited antigens on fetal red cells and was a significant cause 
of fetal and neonatal morbidity and mortality until the introduction of anti- D 
immunoglobulin during pregnancy and shortly after delivery. However, it is still a major 
problem in affected pregnancies (Illanes S. 2008). 
Intrauterine blood transfusion of anaemic fetuses represents one of the great successes of 
fetal therapy. The first approach was intraperitoneal blood transfusion introduced in 1963 
by Liley (Liley AW. 1963). Subsequently Rodeck (Rodeck CH. 1981) described intravascular 
fetal blood transfusion (IVT) by needling of the chorionic plate or umbilical cord vessels 
under direct vision by fetoscopy. In 1982 Bang in Denmark (Bang J. 1982) started IVT by 
umbilical cord puncture under ultrasound guidance which is now widely used by an 
increasingly large number of centres. IVT has produced a marked improvement in survival 
of the anaemic hydropic fetus and can also prevent this complication from developing by 
treating anaemic non-hydropic fetuses where moderate or severe anaemia is detected 
noninvasively by Doppler ultrasonography on the basis of an increase in the peak velocity 
of systolic blood flow or time-averaged mean velocity in the middle cerebral artery (Mari G. 
2000 - Abdel-Fattah SA. 2002). 
The emphasis of current clinical management of HDFN is a non-invasive approach. This 
applies to the detection of fetuses at risk of HDFN with the use of cell-free fetal DNA in the 
www.intechopen.com
 
Fetal Therapy: Where Do We Stand 
 
197 
plasma of pregnant women for the determination of fetal RhD genotype which is now 
available as a service world-wide. In addition when a fetus is antigen positive, the follow-up 
of these fetuses is for the detection of moderate or severe anaemia non-invasively by 
Doppler ultrasonography. When anaemia is suspected, an invasive approach is required in 
order to perform an IVT which should only be attempted when the fetus needs transfusion. 
This approach reduces the iatrogenic conversion of mild to severe disease which occurred as 
a result of the previous management approaches and this change represents one of the 
genuine successes of fetal therapy (Illanes S. 2008). 
3.1.2 Transient aplastic anaemia (parvovirus) 
Parvovirus B19 accounts for about 25% of cases of nonimmune hydrops fetalis in 
anatomically normal fetuses (Hall J. 1994) as a result of fetal anaemia following tropism of 
B19 virus for erythroid precursor cells and the massive destruction of the infected erythroid 
cells and possibly myocarditis resulting in cardiac failure (Yaegashi N. 1999 - Von Kaisenberg 
CS. 2001). The mean gestational age of presentation of hydrops is 22 weeks but there are 
some reports of earlier presentation which might often be undiagnosed (Yaegashi N. 1998 - 
Sohan K. 2000).  
Also some have suggested it may be a cause of apparently unexplained late still birth 
(Norbeck O. 2002). The highest risk for a fetus developing hydrops is when maternal 
infection is before 20 weeks gestation probably due to the rapidly increasing red cell mass 
and short half-life of fetal red cells (Thein AT. 1998). Diagnostic techniques aim at detecting 
maternal antibodies or either viral particles or DNA by PCR in maternal serum, amniotic 
fluid or fetal blood (Von Kaisenberg CS. 2001). 
The fetal loss rate following maternal parvovirus infection is about 10% (PHLS. 1990) but 
this is much higher when hydrops develops, so management is by FBS for diagnosis of 
anaemia followed by transfusion if necessary (Soothill P. 1990). In fact, the rates of death 
among those who receive an intrauterine transfusion are significantly lower than among 
those who did not (Von Kaisenberg CS. 2001 - Fairley CK. 1995). However, consideration 
should be given to the high fetal loss rate in cases of hydrops after fetal blood sampling 
(Maxwell DJ. 1991). Fetal blood results in these cases show a negative Coomb’s test, anaemia, 
thrombocytopenia, and low reticulocyte count (Thein AT. 1998). If the reticulocyte count is 
high at the first transfusion this may indicate recovery already occurring and so a second 
transfusion may not be necessary. Usually FBS is repeated if hydrops returns or more 
recently when Doppler studies suggest worsening anaemia. 
In spite of some reports of hydrops due to fetal parvovirus infection resolving without 
treatment (Pryde PG. 1992 - Rodis JF. 1998), in our view if non-immune hydrops presents 
without obvious fetal malformations and anaemia is expected from the Doppler results, 
even if the mother does not give a clear history of parvovirus exposure, FBS should still be 
done urgently without waiting for maternal confirmatory tests and intra-uterine transfusion 
be done if there is evidence of severe fetal anaemia. 
In contrast with other causes of fetal anaemia and hydrops, fetal complications caused by 
hPV B19 have the potential to resolve as the fetus mounts its own immune response (Lamont 
R. 2011). So if other signs of fetal well-being are present, it might be possible to continue 
with conservative measurements (Lamont R. 2011). 
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3.2 Amniotic fluid management  
Amniotic fluid surrounds the fetus in intrauterine life providing a protected, low-resistance 
space suitable for fetal movements, growth and development. Disturbance of the balance 
between amniotic fluid production and consumption leads to oligo- or polyhydramnios, 
both of which are associated with poor perinatal outcome related to the degree of fluid 
volume change (Chamberlain PF. 1984). 
Severe polyhydroamnios can cause maternal abdominal discomfort, respiratory 
embarrassment and preterm delivery (Kyle PM. 1997 – Phelan JP. 1990). Amniotic fluid 
reduction can relieve maternal symptoms with severe polyhydramnios and prolong the 
gestation in both singleton and multiple pregnancies and is one of the possible treatments 
for TTTS (Kyle PM. 1997 - Wee LY. 2002). Abruption can be a complication of removal of 
large volumes of amniotic fluid and this risk has been estimated at about 3-4% (Leung WC. 
2004). Common criteria for amniotic fluid drainage are AFI > 40 cm or the deepest single 
pool of >12 cm but many prefer to make the decision mostly on maternal discomfort (Thein 
AT. 1998). Removal of a small volume can rapidly reduce amniotic fluid pressure but it 
usually re-accumulates quickly and approximately 1 litre needs to be removed for every 
10cm the AFI is elevated (Kyle PM. 1997 - Abdel-Fattah SA. 1999). The procedure often has to 
be repeated in order to prolong gestational age until maturity allows delivery. The insertion 
of a tube to achieve chronic long-term drainage has been tried in the past but there is a high 
risk of infection and no evidence supporting this approach. 
Oligohydramnios is found in 3-5% of pregnancies in the third trimester, but severe cases 
relating to impaired outcome are less common (Kyle PM. 1997). The significance of this 
finding relates mostly to the underlying cause, so the prognosis and the possibility of 
treatment depends on the aetiology. Attempts at therapy focus on restoring the amniotic 
fluid to allow continue development of the lungs during the canalicular phase. Quintero et 
al (Quintero RA. 1999) described effective resealing in cases of iatrogenic previable PPROM 
by intra-amniotic injection of platelets and cryoprecipitate although this approach has not 
been reported to work after spontaneous membrane rupture. Some reports have also shown 
that in pregnancies with preterm premature rupture of membranes (PPROM) with 
oligohydramnios at <26 weeks' gestation, serial amnioinfusions improve the perinatal 
outcome when compared to those with persistent oligohydramnios (Locatelli A. 2000 - De 
Santis M. 2003). Fisk et al have recently described an amnioinfusion test procedure to try 
and pre-select cases of midtrimester PPROM which may benefit from serial amnioinfusion. 
A quarter of patients who retained infused fluid went on to subsequent serial amnioinfusion 
and prolongation of pregnancy with decrease in the risk of pulmonary hypoplasia (Tan LK. 
2003). However, there are risks of procedure related complications such as chorioamnionitis, 
placental abruption and extreme prematurity, so ideally a large series in a prospectively 
randomised trial would be needed to assess the benefits. 
Amnioinfusion has also been used to prevent or relieve variable decelerations from 
umbilical cord compression in cases of rupture of membranes and to dilute meconium when 
present in the amniotic fluid and so reduce the risk of meconium aspiration during labour. 
A Cochrane review found that amnioinfusion for oligohydramnios helps when the baby 
shows signs of distress. If the baby shows no signs of distress from oligohydramnios, then 
amnioinfusion is not helpful. So there is no role for prophylactic amnioinfusion (Novikova N. 
1996). Another studies shows improvements in perinatal outcome when it is used to dilute 
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meconium, only in settings where facilities for perinatal surveillance are limited (Xu H. 2007 
- Hofmeyr GJ. 2010). 
3.3 Shunting 
3.3.1 Pleuro-amniotic shunting  
A pleural effusion may be an isolated finding or may occur in association with hydrops 
fetalis. When severe, this condition can produce hydrops, pulmonary hypoplasia by lung 
compression and polyhydramnios with secondary risks of preterm delivery (Phelan JP. 
1990). When due to a reversible cause such as chylothorax, the treatment of this condition by 
pleuro-amniotic shunting can be a very effective method (Sohan K. 2001) and can reverse the 
complications and prevent death. However, drainage does not help cases in which the 
pleural effusion is caused by an underlying progressive disease, or when the effusions are 
mild and so will not produce secondary effects or when the problem is diagnosed so late 
that pulmonary hypoplasia has already occurred and is irreversible.  
When making the difficult decision of whether or not to shunt, the risks of thoracoamniotic 
shunting must be considered. The recommendation is that large pleural effusions, especially 
those with hydropic changes, should be seen urgently in a center that can offer tertiary level 
ultrasound examination, aspiration and shunting because, with appropriate treatment, 50% 
of fetuses survive (Smith RP. 2005). Recently Yinon et al. conducted a retrospective study of 
88 fetuses with large pleural effusions who underwent pleuroamniotic shunting, to evaluate 
perinatal outcome associated to the procedure. They concluded that carefully selected 
fetuses with primary pleural effusions can benefit from pleuroamniotic shunting, allowing 
hydrops to resolve with a survival rate of almost 60% (Yinon Y. 2010). 
Another approach for management of fetal chylothorax that is under evaluation is the use of 
pleurodesis with OK-432. First case-reports about its utility where published in 2001 revealing 
rapid and effective control of pleural effusion (Tanemura M. 2001 – Okawa T 2001). A posterior 
review conducted by Chen et al. pooled a total of 9 cases, concluding that the success of the 
procedure depends on the complete aspiration of the pleural cavity and the demonstration of 
adhesions by ultrasonography following the procedure (Chen M. 2005). A recent report 
published last year, that included a total of 45 cases show that this treatment is only useful in 
those cases without hydrops, converting the use of OK-432 pleurodesis in a plausible 
alternative to the classic management with thoracoamniotic shunting (Yang YS. 2011). 
3.3.2 Vesico-amniotic shunting 
Lower urinary tract obstruction has a significant impact on perinatal morbidity and 
mortality, related principally to pulmonary hypoplasia and renal impairment that produce 
at least a 40% of mortality (Nakayama DK. 1986 - Freedman AL. 1996). Animal models of 
releasing obstruction have been very successful but these models are often different from 
human congenital urinary tract obstruction (Agarwal SK. 2001). The insertion of a double 
pig-tailed vesico-amniotic catheter is the most commonly used method to relieve this 
obstruction in vivo but complications are quite common, including failure of drainage or 
migration of the shunt, premature labour, urinary ascites, chorioamnionitis and iatrogenic 
gastroschisis (Coplen DE. 1997). The main concern about vesico-amniotic shunting is that by 
the time severe obstructive uropathy is detected, renal function may be already severely and 
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irreversibly damaged (Freedman AL. 1996). Needle drainage has been used to obtain an 
assessment of renal function and helping to identifying fetuses with potential to benefit 
from in uterus surgical intervention (Agarwal SK. 2001). Sometimes needle aspiration can 
appear to be therapeutic for megacystis in very early in the second trimester perhaps as a 
result of releasing urethral oedema secondary to pressure (Carroll SG. 2001).  
Recent data about antenatal bladder drainage appears to improve perinatal survival in cases 
of congenital lower urinary tract obstruction, but may confer a high residual risk of poor 
postnatal renal function, based on observational studies (Morris RK. 2010). Currently, a 
clinical trial (PLUTO trial) comparing conservative management to vesicoamniotic shunting 
in singleton fetuses below 28 weeks gestation with isolated bladder outflow obstruction is at 
development (PLUTO trial. 2007). 
3.4 Laser treatment 
Monochorionic (MC) twins account for 20% of spontaneous twin pregnancies and almost 5% 
occur as a result of medically assisted reproduction (Chalouhi GE. 2011). Twin-twin 
transfusion syndrome (TTTS) affects 10% to 15% of monozygous twin pregnancies with 
monochorionic placentation (Chalouhi GE. 2011 - Sebire NJ. 1997 - Carroll SG. 2002).  
Without treatment, there is a very high risk of perinatal mortality and perinatal morbidity 
due to preterm delivery but also as a result of acquired brain injury in utero (Denbow ML. 
1998). When TTTS is of early onset, the prognosis is even worse and interruption of the 
vascular anastomosis by fetoscopic laser ablation is a sensible treatment that has been 
used since the beginning of the 1990s (De Lia JE 1990). TTTS management has 
encompassed non-specific, sometimes symptomatic, treatments including 
amnioreduction, septostomy and even expectant management. To date, the only treatment 
addressing the pathophysiology of the syndrome is fetoscopic selective laser coagulation 
of placental vessels (SLCPV) (Chalouhi GE. 2011). 
With this treatment, in a third of pregnancies both twins survive, in another third one twin 
survives and in the remaining third both twins die (Ville Y. 1995). The recently published 
Eurofetus study showed that laser therapy is associated with improved perinatal outcome 
compared with amnioreduction in women presenting with TTTS before 26 weeks’ gestation 
(Senat MV. 2004). To improve these results we need better ways of identifying all arterial-
venous (A-V) anastomoses before ablation, which will enable a true rendering into a DC 
placenta with minimal destruction of viable placental territory. There have been some 
attempts of delineating placental vascular anatomy in utero with contrast agents and power 
Doppler but without clear success (Denbow ML. 2000). 
Laser ablation has also been used successfully to treat acardiac twin pregnancies that 
complicate 1% of monozygous twin pregnancies with monochorionic placentation (Moore 
TR. 1990) and are associated with congestive cardiac failure in the pump twin leading to 
polyhydramnios and preterm delivery with a reported perinatal mortality in untreated cases 
as high as 55% (Tan TY. 2003). Laser or diathermy ablation is used to occlude the cord or the 
pelvic vessels within the abdomen of the acardiac twin (Rodeck C. 1998 - Soothill P. 2002). A 
recent review suggests that intrafetal ablation is the treatment of choice for acardiac twins 
because it is simpler, safer and more effective when compared with the cord occlusion 
techniques (Soothill P. 2002). 
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3.5 Fetoscopic / Open fetal surgery 
Although most malformations diagnosed prenatally are best managed after birth, a few 
severe ones may be better treated before birth. The fetal malformations that warrant 
consideration for open surgical correction in uterus are those that interfere with normal 
growth, development and are life-threatening, so that correction of the defect may prevent 
these effects. At present, only a few malformations have been successfully corrected, 
including fetal myelomeningocele (MMC) and congenital diaphragmatic hernia (CDH). 
3.5.1 Hydrocephaly and neural tube defects 
Fetal MMC can produce (Johnson MP. 2003) obstructive hydrocephalus in up to 85% of cases 
requiring ventriculoperitoneal shunting. MMC can have other long term sequelae such as 
motor impairment of the legs and loss of bowel and bladder control.  The damage may be 
due to the defect in the bony spinal column exposing the spinal cord to the trauma from the 
amniotic fluid and the uterine environment (Evans MI. 2002) raising the possibility of 
covering the spinal cord in the uterus to avoid the damage. The accumulated experience 
with fetal MMC repair has been encouraging and suggests a decreased need for 
ventriculoperitoneal shunting, arrest or slowing of progressive ventriculomegaly, and 
consistent resolution of hindbrain herniation in the short term follow up (Johnson MP. 2003). 
However, further long-term follow-up is needed to evaluate neurodevelopment and bladder 
and bowel function. Since 2003 the MOMS trial is recruiting patients to assess the better 
management for these cases. So most centres still await for result before recommend the 
clinical intervention (Luks FI. 2011). 
3.5.2 Congenital diaphragmatic hernia 
Congenital diaphragmatic hernia has a high mortality rate, and many clinical and 
experimental efforts have been made in order to reduce it. Open fetal repair of the 
diaphragmatic defect was attempted but with an unacceptable high mortality rate and so 
has been abandoned (Evans MI. 2002). Fetoscopic temporary tracheal occlusion, have emerge 
as an alternative to open fetal surgery on the basis that the accumulation of lung fluid 
secretions can expand the lungs and so reduce the herniated viscera and avoid pulmonary 
hypoplasia. This approach may improve lung growth and development (Sydorak RM. 2003); 
however, complications related to tracheal dissection, premature delivery and late 
morbidity are significant (Deprest J. 2004). New techniques have been proven in 
experimental stage with less invasive approach but most studies have felt to prove any 
improvement of survival or morbidity rates when compared intrauterine fetal endoscopic 
tracheal occlusion approach with optimal postnatal care. However, there is a small group of 
extremely severe cases that could benefit from prenatal intervention (Luks FI. 2011). 
The exact definition of this subgroup of patients is still being debated. In 2003 Harrison et al. 
Correlated survival rates with lung-to-head ratio (LHR). Using this ratio good prognosis 
(100% survival) was associated with an LHR > 1.4. Poor prognosis (less than 30% survival) 
was associated with an LHR < 1.0 (Harrison MR. 2003). 
Actually, a RCT of Luks et al. is recruiting patients to evaluate the benefits of fetal tracheal 
occlusion with a detachable balloon for an LHR < 0.9 (Luks FI. 2008). 
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4. Interventions in experimental stages 
4.1 Ablation of tumours 
Some tumours may growth to massive proportion in uterus, inducing high-output failure 
leading to fetal hydrops that end most uniformly in fetal demise. Fetal sacrococcygeal 
teratoma is a good example of this and surgery may have a role before the onset of hydrops 
in order to avoid this complication or after in order to resolve it (Luks FI. 2011). Ablation of 
the majority of the tumour tissue is not usually necessary and perhaps only ligation or 
coagulation of the vascular steal can reverse or avoid the high-output fetal heart failure (Paek 
BW. 2001). Open fetal surgery with a high incidence of technique related complications has 
been moving to less invasive approach such as radiofrequency ablation and fetoscopic 
resection (Hirose S. 2003) but more studies are needed to assess the impact of these types of 
managements and what groups of fetus benefit from them. With cervical teratomas another 
possibility for tracheal obstruction can be the EXIT procedure where the fetus is partially 
delivered, maintaining the uteroplacental circulation in order to perform the surgery and 
achieve adequate ventilation (Murphy DJ. 2001). 
4.2 Stem cell transplantation 
At the present time, the most likely and eminent application of stem cell therapy to the 
fetus is in utero hematopoietic stem cell transplantation (Matthew T. 2009). Bone marrow 
transplantation of normal haematopoietic stem cells can sustain normal haemopoeisis and 
be an alternative in treatment of lethal haematological disease. In the case of congenital 
disease like haemoglobinopathies, immunodeficiency disorders and inborn errors of 
metabolism that can be diagnosed prenatally and cured or improved by the engraftment 
of normal stem cells are theoretically an attractive alternative for the in utero 
transplantation of stem cells (Evans MI. 2002). The unique characteristic of the 
hematologic and inmunologic system in the human fetus, could circumvent the postnatal 
problems of transplantation, such as graft-verus-host disease, and the remarkable ability 
of stem cells to proliferate, differentiate and become tolerant to host antigens are 
encouraging. However, most research on stem cell therapy to date has focused on 
disorders of old age that are not genetic. So, very little is known about the disorders that 
can occur in utero and how stem cells might be of benefit (Mummery C. 2011). Finally, 
there is a small amount of evidence about safety and effectiveness in animals for transfer 
of treatment to fetuses at the present time (Mummery C. 2011). 
4.3 Gene therapy  
The goal of gene therapy is to treat disease before damage secondary to the gene pathology 
is produce. Fetal gene therapy for many disorders already has been demonstrated in rodent 
and large animal models (Matthew T. 2009). Some reports show that using a percutaneous 
ultrasound-guided injection of gene transfers in the airway or in the amniotic cavity in 
animal, provided levels of gene expression in lung and intestine that could be relevant for a 
therapeutic application (David A. 2003 - Garrett DJ. 2003). In spite of the large amount of 
experimentation already made in this field, today we are still unsure whether or not this 
technique will provide the desired therapeutic effect and whether expression of the 
transferred genes will provide real clinical benefit (Matthew T. 2009). Safety concerns need to 
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be investigated extensively in appropriate preclinical animal models before application in 
humans. The ethics of fetal gene therapy also need to be considered. 
5. Conclusions 
Much has been achieved in the prevention, diagnosis and management of fetal pathology. 
This has allowed the development of interventions that have proven to be beneficial and 
safe for both fetus and mother. However, much remains to be investigated. The rapid 
progress in molecular and genetic research continues to be promising. However, the ethical 
and moral implications associated constitute a very important point that should not be 
omitted. 
This article is a review of the evidence available at the time of publication and at no stage 
intended to be the basis for decision making and behaviours in particular cases, were 
different variables have to be pondered that exceed the scope of this chapter. It is the duty of 
the specialists to inform their patients and taking into account all the edges and risk for each 
management.  
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